Health Care: Drugs

Regulus Therapeutics Inc (RGLS: NASDAQ)

$7 0.24 | 3.55%
04/16/14 - 03:41 PM ET
Company Cash Flow
Dec 2013 Dec 2012 Dec 2011
Cash Flow From Operating Activities
Net Income (Loss) -18.67M -17.41M -7.60M
Operating Gains/Losses 1.12M 4.72M -1.00K
Extraordinary Gains / Losses 0.00 0.00 0.00
(Increase) Decrease In Receivables -79.00K 0.00 0.00
(Increase) Decrease in Inventories 0.00 0.00 0.00
(Increase) Decrease In Other Current Assets 0.00 0.00 0.00
(Decrease) Increase In Payables 860.00K -189.00K -793.00K
(Decrease) Increase In Other Current Liabilities 1.30M 657.00K -174.00K
(Increase) Decrease In Other Working Capital -16.83M 823.00K -8.64M
Other Non-Cash Items 3.42M 1.55M 825.00K
Net Cash From Continuing Operations -28.33M -8.72M -15.06M
Net Cash From Discontinued Operations 0.00 0.00 0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities -28.33M -8.72M -15.06M
Sale of Property, Plant & Equipment 0.00 0.00 0.00
Cash Used for Investing Activities
Sale of Short-Term Investments 31.95M 33.08M 54.58M
Purchases of Property, Plant & Equipment -835.00K -1.43M -598.00K
Acquisitions 0.00 0.00 0.00
Purchases of Short-Term Investments -72.00M -62.04M -50.66M
Other Cash from Investing Activities 0.00 0.00 0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities -40.89M -30.38M 3.32M
Issuance of Debt 0.00 5.00M 0.00
Cash Used for Financing Activities
Issuance of Capital Stock 594.00K 65.93M 58.00K
Repayment of Long-Term Debt 0.00 -445.00K -412.00K
Repurchase of Capital Stock 0.00 0.00 0.00
Payment of Cash Dividends 0.00 0.00 0.00
Other Financing Charges, Net 45.88M 0.00 0.00
Net Cash From Financing Activities 46.47M 70.48M -354.00K
Effect of Exchange Rate Changes 0.00 0.00 0.00
Net Change in Cash & Cash Equivalents -22.74M 31.38M -12.09M

Portfolios with RGLS

Latest RGLS Headlines from TheStreet

More Financial News for RGLS

Press Releases for RGLS

See All Press Releases

Partner Headlines for RGLS

brokerage partners
connect with Stockpickr
Fan us on FaceBook
Follow us on Twitter